Most people who contract Chikungunya virus experience joint pain and fever, then recover fully. But a rare subset develops devastating neurological complications — encephalitis and myelitis — and until now, why only certain individuals crossed that threshold remained poorly understood. A new finding reframes this question entirely: the vulnerability may be pre-existing, written into the immune system long before the virus arrives.
Published in PNAS, the study found that autoantibodies targeting type I interferons — the immune system's frontline antiviral signaling molecules — were detectable in 35% of patients who developed central nervous system complications from Chikungunya virus (CHIKV) infection. These autoantibodies effectively neutralize interferon-α and/or interferon-β, disabling a critical layer of innate immunity that would normally contain viral replication and prevent neurological invasion. The cohort studied included patients presenting with confirmed CHIKV encephalitis or myelitis, making this one of the more mechanistically detailed analyses of severe arboviral neurological disease to date.
This finding connects to a broader and rapidly expanding paradigm established largely through work on COVID-19 and influenza: that pre-formed anti-interferon autoantibodies — estimated to exist in roughly 1–4% of the general population, with prevalence rising sharply with age — silently predispose individuals to life-threatening infections. The same mechanism has been implicated in severe West Nile virus neuroinvasion and yellow fever vaccine-associated viscerotropic disease, suggesting this immunological liability cuts across multiple RNA viruses with neurotropic potential. For adults over 60, in whom these autoantibodies are significantly more prevalent, the risk calculus around mosquito-borne illness in endemic regions may warrant reconsideration. The practical implication is not yet clinical — no screening protocol exists — but the mechanistic link is strong enough to justify prospective screening trials and to reorient research toward immunological profiling rather than purely virological risk factors.